Navigation Links
Part I. Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
Date:7/18/2014

at Shire may pay dividends of up to 15 pence per Shire Share in aggregate prior to closing of the Transaction.

12.
Shire Share SchemesParticipants in the Shire Share Schemes will be contacted regarding the effect of the Merger on their rights under the Shire Share Schemes and appropriate proposals will be made to such participants in due course.

13.
The Merger and the AbbVie Merger13.
Structure of the MergerIt is intended that the Merger will be implemented by means of a court-sanctioned scheme of arrangement between Shire and the Scheme Shareholders under Article 125 of the Companies Law.

The purpose of the Scheme is to provide for New AbbVie to become the direct or indirect owner of the entire issued and to be issued share capital of Shire. In order to achieve this, the Scheme Shares will either be transferred to New AbbVie (or a subsidiary of New AbbVie) or cancelled and new AbbVie Shares issued to New AbbVie. In consideration for this, the Scheme Shareholders will receive cash and New AbbVie Shares on the basis set out in paragraph 2 of Part II of this announcement. The transfer of those Scheme Shares to, or cancellation and issue of new AbbVie Shares to, New AbbVie (or a subsidiary of New AbbVie) will result in Shire becoming a direct or indirect wholly owned subsidiary of New AbbVie.

The Scheme requires approval by Shire Shareholders by the passing of a resolution at the Court Meeting. The Scheme must be approved at the Court Meeting by a majority in number of the holders of Scheme Shares present and voting, either in person or by proxy, representing not less than three-fourths of the voting rights of such Scheme Shareholders. In addition, the implementation of the Scheme will require approval by the passing of certain resolutions at the General Meeting to be held immediately after the Court Meeting.

The Scheme must also be sanctioned by the Court. All Scheme Shareholders are entitled to attend the Scheme Court Heari
'/>"/>

SOURCE AbbVie Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts To 20
2. aTyr Pharma Announces Publication of a Rare Muscle Disease Associated with Regulation of a Potential Physiocrine
3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
4. Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiologys Cardiovascular Interventions Journal
5. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
6. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
7. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
8. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
9. SI-BONE, Inc. Announces Publication of Postmarket Surveillance Safety Data on First 5,319 Patients Treated with iFuse Implant System
10. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
11. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 This ... studies the current and future prospects of the ... patient,s health and assists medical practitioners in deciding ... disease progression during treatment. Multi-parameter patient monitoring is ... chronic disease. Geriatric population is observed to be ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 ... is an X-linked disease, which generally affects the ... degeneration and weakness. The disease is caused due ... in the lack of production of dystrophin (a ... individuals. The lack of dystrophin weakens muscle function, ...
(Date:9/2/2015)... Pa. , Sept. 2, 2015 ... increases, diversifies revenue base with highly profitable specialty ... , Near-term growth potential with 11 product ... include Paragraph IV certifications  , Provides medium ... candidates in development, including eight controlled substances ...
Breaking Medicine Technology:Multi-parameter Patient Monitoring Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Multi-parameter Patient Monitoring Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6
(Date:9/2/2015)... Athyn, PA (PRWEB) , ... September 02, 2015 , ... ... Heilman Hall at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, Pa ... Inc., will host a day-long seminar featuring New York Times best-selling author Sam Keen ...
(Date:9/2/2015)... San Jose, CA (PRWEB) , ... September 02, ... ... connectivity for Internet of Things, announces its latest addition to its screen mirroring ... the existing award-winning Splashtop Extended Wireless Display, which operates in local WIFI setting, ...
(Date:9/2/2015)... ... September 02, 2015 , ... Michael Elliot Media announces ... a plus-size actress as the primary love interest in the film. The campaign is ... film, significantly affects how and what we think,” Michael Elliot, an award-winning screenwriter and ...
(Date:9/2/2015)... ... , ... Ericson is a noted speaker and educator in the field of ... Education for the Association for Clinical Documentation Improvement Specialists (ACDIS) where she developed and ... serves as a CDI subject matter expert for a variety of HCPro and ACDIS ...
(Date:9/2/2015)... ... September 02, 2015 , ... A recent survey by Consumer Reports ... year and its negative impact on consumers. It was reported that 33% are paying ... paying as much as an extra $100 compared to last year. Among the drugs ...
Breaking Medicine News(10 mins):Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:Award-Winning Screenwriter Uses Crowdfunding Campaign to Change Hollywood’s Ideal of Beauty to Include PLUS-SIZE Women 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2
... data from a Phase 2 clinical trial of GVAX ... Johns Hopkins Sidney Kimmel Cancer Center. The trial ... GVAX after surgical resection of their tumor and adjuvant ... patients was previously reported to be 26.8 months, a ...
... end, even if it is all subtle, as in Canada ... pin down is more dangerous to mental health than ... living in Canada. ,"We found that the subtle ... such as symptoms of depression and anxiety," said lead author ...
... Annual Meeting of SNM, the world's largest society ... German researchers stated that early metabolic imaging with ... to chemotherapy for esophageal cancer. ,"This ... from early metabolic response assessment to clinical decision ...
... announced today that HHS has awarded a contract for $500 ... manufacture and deliver 20 million doses of a next generation ... would be recommended in the event of a smallpox outbreak ... immune systems. The full supply of the vaccine will be ...
... welcomed a new study to be published today in ... contribute to the steadily mounting evidence that undermines ... obesity. A report issued last Friday by the Federal ... Archives study found that "children do not currently see ...
... interim findings from its Phase II, multi-center clinical ... anthracycline currently in development for the treatment of ... indicate favorable interim results in terms of response ... current treatment standard, topotecan, in second-line treatment of ...
Cached Medicine News:Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 2Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 3Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 4Health News:Koreans in Canada Feel Put Down by Subtle Racism 2Health News:Esophageal Cancer Patients' Positive Responses to Chemotherapy Accurately Identified by PET 2Health News:HHS Buys Next Generation Smallpox Vaccine 2Health News:HHS Buys Next Generation Smallpox Vaccine 3Health News:New Studies: Commercials Aren't Making Kids Fat 2Health News:Amrubicin Shows Encouraging Results for Small Cell Lung Cancer Treatment 2
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... helps provide protection to the exposed airway of ... lightweight making it ideal for active young children ... of heat and moisture recovery, it ensures patient ... and filters have ISO standard tapered ends to ...
... T helps provide protection to the exposed airway ... extremely lightweight making it ideal for active young ... rate of heat and moisture recovery, it ensures ... HMEs and filters have ISO standard tapered ends ...
... digital models cover the range from 2ul to ... Volume lock design prevents inadvertent volume change. ... grip. Whole pipette is autoclavable at 121C(250F). ... all polypropylene. Suitable for one-handed operation. ...
Medicine Products: